PSI Developed A New Promising Radiopharmaceutical Successfully Tested
PSI Developed A New Promising Radiopharmaceutical Successfully Tested A promising radiopharmaceutical against metastatic neuroendocrine tumours has been successfully tested for the first time in patients at the University Hospital Basel, Switzerland. The new radionuclide terbium-161 was developed at the Paul Scherrer Institute (PSI, ENS Corporate Member). This isotope has the property that when the radioisotope…